Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rocket Pharmaceuticals (RCKT) Equity Average: 2016-2025

Historic Equity Average for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to $333.9 million.

  • Rocket Pharmaceuticals' Equity Average fell 6.51% to $333.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $333.9 million, marking a year-over-year decrease of 6.51%. This contributed to the annual value of $477.9 million for FY2024, which is 2.69% down from last year.
  • Rocket Pharmaceuticals' Equity Average amounted to $333.9 million in Q3 2025, which was down 12.85% from $383.2 million recorded in Q2 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' Equity Average peaked at $516.8 million during Q4 2023, and registered a low of $333.9 million during Q3 2025.
  • Its 3-year average for Equity Average is $425.7 million, with a median of $430.9 million in 2023.
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Equity Average surged by 91.81% in 2021, and later dropped by 24.33% in 2024.
  • Over the past 5 years, Rocket Pharmaceuticals' Equity Average (Quarterly) stood at $470.2 million in 2021, then fell by 8.87% to $428.5 million in 2022, then grew by 20.61% to $516.8 million in 2023, then fell by 23.28% to $396.5 million in 2024, then dropped by 6.51% to $333.9 million in 2025.
  • Its last three reported values are $333.9 million in Q3 2025, $383.2 million for Q2 2025, and $437.7 million during Q1 2025.